Cerixen 150 mg (Ceritinib INN) – Everest Pharmaceuticals Ltd.

Targeted ALK Inhibitor for Advanced Non-Small Cell Lung Cancer

📌 Indications:

Cerixen® 150 mg is indicated for:

• ALK-positive metastatic non-small cell lung cancer (NSCLC)
• Patients with disease progression following crizotinib treatment
• First-line treatment of ALK-positive advanced NSCLC

💊 Pharmacology:

Ceritinib is a highly selective ALK tyrosine kinase inhibitor. It blocks the activity of ALK fusion proteins responsible for uncontrolled cell growth and proliferation. By inhibiting ALK signaling pathways, Cerixen® suppresses tumor progression and induces cancer cell death.

💉 Dosage & Administration:

• Recommended dose: 450 mg once daily with food (three 150 mg capsules).
• Continue treatment until disease progression or unacceptable toxicity occurs.
• Dose modifications may be necessary based on adverse reactions.
• Use under the supervision of an experienced oncologist.

⚠️ Precautions & Warnings:

• Monitor liver function tests regularly.
• Use caution in patients with interstitial lung disease or pneumonitis.
• Monitor blood glucose levels in diabetic patients.
• QT interval prolongation and bradycardia may occur.
• Gastrointestinal toxicity is common and should be managed appropriately.

❌ Contraindications:

• Hypersensitivity to Ceritinib or any component of the formulation.

🤰 Pregnancy & Lactation:

• May cause fetal harm when administered during pregnancy.
• Effective contraception is recommended during treatment.
• Breastfeeding should be discontinued during therapy and for at least two weeks after the last dose.

⚕️ Side Effects:

Common adverse effects include:

• Diarrhea
• Nausea and vomiting
• Abdominal pain
• Fatigue
• Elevated liver enzymes
• Hyperglycemia
• Decreased appetite

Serious adverse reactions may include:

• Hepatotoxicity
• Interstitial lung disease/pneumonitis
• QT prolongation
• Severe gastrointestinal toxicity

🧊 Storage Conditions:

• Store below 30°C in a dry place.
• Protect from light and moisture.
• Keep out of reach of children.